Geode Capital Management
ELTX icon

Geode Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Geode Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$754K Buy
414,165
+102,811
+33% +$285K ﹤0.01% 3414
2026
Q2 		$1.22M Buy
311,354
+176,190
+130% +$1.77M ﹤0.01% 3312
2026
Q1 		$1.45M Buy
135,164
+2,646
+2% +$25.5K ﹤0.01% 3239
2025
Q4 		$1.06M Buy
132,518
+2,832
+2% +$25.7K ﹤0.01% 3363
2025
Q3 		$1.42M Buy
129,686
+8,855
+7% +$89.6K ﹤0.01% 3294
2025
Q2 		$933K Buy
120,831
+43,364
+56% +$270K ﹤0.01% 3346
2025
Q1 		$477K Buy
77,467
+6,746
+10% +$52.3K ﹤0.01% 3561
2024
Q4 		$347K Sell
70,721
-853
-1% -$4.2K ﹤0.01% 3715
2024
Q3 		$360K Buy
71,574
+66
+0.1% +$292 ﹤0.01% 3705
2024
Q2 		$294K Buy
71,508
+23,812
+50% +$201K ﹤0.01% 3777
2024
Q1 		$363K Buy
47,696
+3,352
+8% +$16.8K ﹤0.01% 3725
2023
Q4 		$370K Buy
44,344
+16,470
+59% +$107K ﹤0.01% 3727
2023
Q3 		$236K Buy
27,874
+3,705
+15% +$35.3K ﹤0.01% 3914
2023
Q2 		$230K Buy
24,169
+7,429
+44% +$68.1K ﹤0.01% 3983
2023
Q1 		$97.1K Sell
16,740
-104
-0.6% -$693 ﹤0.01% 4344
2022
Q4 		$136K Sell
16,844
-45
-0.3% -$409 ﹤0.01% 4278
2022
Q3 		$155K Buy
16,889
+8,194
+94% +$85.6K ﹤0.01% 4348
2022
Q2 		$99K Sell
8,695
-15,893
-65% -$254K ﹤0.01% 4596
2022
Q1 		$521K Buy
24,588
+2,123
+9% +$47.9K ﹤0.01% 3914
2021
Q4 		$651K Sell
22,465
-2,707
-11% -$137K ﹤0.01% 3912
2021
Q3 		$2.46M Buy
25,172
+15,043
+149% +$1.63M ﹤0.01% 3261
2021
Q2 		$1.32M Buy
10,129
+598
+6% +$86.3K ﹤0.01% 3462
2021
Q1 		$1.72M Buy
+9,531
New +$1.84M ﹤0.01% 3327

Other funds holding ELTX

Shah Capital Management
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Geode Capital Management's ELTX Position: Q3 2026 in Review

Geode Capital Management increased its Elicio Therapeutics (ELTX) stake by 33% in Q3 2026, buying an estimated $285K and bringing the position to 414,165 shares worth $754K. The position accounts for ﹤0.01% of the portfolio, ranked #3414.

Geode Capital Management first reported a position in ELTX in Q1 2021 and has held it in 23 quarters since. The position peaked at $2.46M in Q3 2021. 57 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • Geode Capital Management held 414,165 shares of Elicio Therapeutics worth $754K as of Q3 2026.
  • Geode Capital Management bought 102,811 Elicio Therapeutics shares in Q3 2026, an estimated $285K.
  • Elicio Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3414 holding.
  • Geode Capital Management first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 23 quarters since.
  • Geode Capital Management's Elicio Therapeutics position peaked at $2.46M in Q3 2021.
  • 57 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.